Efficacy and Safety of Tislelizumab Combined With Bevacizumab and Albumin Paclitaxel in Lung Adenocarcinoma
PHASE2CompletedINTERVENTIONAL
Enrollment
24
Participants
Timeline
Start Date
March 1, 2021
Primary Completion Date
June 1, 2023
Study Completion Date
December 1, 2023
Conditions
Lung Adenocarcinoma Stage IV
Interventions
DRUG
Tislelizumab
Tislelizumab, 200mg, Q3W ,use until disease progression
Trial Locations (1)
510120
Zhou Chengzhi, Guangzhou
All Listed Sponsors
lead
Zhou Chengzhi
OTHER
NCT04310943 - Efficacy and Safety of Tislelizumab Combined With Bevacizumab and Albumin Paclitaxel in Lung Adenocarcinoma | Biotech Hunter | Biotech Hunter